A two part study to separately evaluate the effect of 4-week treatment with GW501516X relative to placebo on cardiac energetics in a randomized, single-blind, repeat dose, parallel group design in healthy male subjects.
Phase of Trial: Phase I
Latest Information Update: 16 Mar 2012
At a glance
- Drugs GW 501516 (Primary)
- Indications Heart failure; Hyperlipidaemia
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 02 Feb 2007 Status changed from recruiting to discontinued.
- 06 Nov 2006 New trial record.